Cellectar Biosciences, Inc. (CLRB) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cellectar Biosciences, Inc. on August 13, 2026. The filing serves to announce the company's financial results for the quarter ended June 30, 2026, and provides a corporate update. The company is incorporated in Delaware and trades on The Nasdaq Capital Market under the symbol CLRB.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The 8-K acts as a notification that these results have been issued via a press release (Exhibit 99.1) but does not list the figures within the body of this specific document.
Material Changes
The filing does not detail specific material changes versus prior periods. It references a press release for the Second Quarter 2026 results and corporate updates, but the text of the 8-K itself contains no comparative data or descriptions of operational changes.
Guidance, Outlook, and Risks
The filing indicates that management provided a corporate update alongside the financial results. However, the text of this 8-K does not include specific guidance, forward-looking statements, risk factors, contingencies, or unusual items. These details are contained within the referenced press release (Exhibit 99.1).
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2026 revenue, net loss, and cash burn figures.
- Verify the company's cash runway and liquidity position as detailed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the corporate update.
- Confirm if there were any changes to the company's financial guidance or strategic outlook.